On February 12, 2026, BioXcel Therapeutics, Inc. reported the completion of a market assessment for IGALMI®, revealing 2.3 million bipolar disorder and schizophrenia patients experience acute agitation at home, with up to 1.8 million potentially eligible for treatment. This highlights a significant need for their product as current options are limited.